Wanbury Ltd
Tue 7/07/2026,16:6:11 | NSE : WANBURY
Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
Open
₹ 287.25
Previous Close
₹ 283.65
Volume
54090
Mkt Cap ( Rs. Cr)
₹974.29
High
₹ 287.25
Low
₹ 277.90
52 Week High
₹ 315.20
52 Week Low
₹ 161.50
Book Value Per Share
₹ 41.34
Dividend Yield
0.00
Face Value
₹ 10.00
What’s Your Call?
Collective community sentiment on Wanbury Ltd
Your Vote -
Buy
50.00%
Hold
16.67%
Sell
33.33%
50.00%
6 users have voted
Market Depth
How many stocks are available to buy or sell and at what prices.
Buy Order Quantity
NaN%
Sell Order Quantity
NaN%
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Option Chain
Analyzes market sentiment, predicts Wanbury Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Wanbury - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Wanbury - Investor Presentation
-
Wanbury - Announcement under Regulation 30 (LODR)-Investor Presentation
-
Wanbury - Announcement under Regulation 30 (LODR)-Change in Management
-
Wanbury - Board Meeting Outcome for Outcome Of The Board Meeting Dated 26.06.2026
-
Wanbury - Change in Auditors
-
Wanbury - Outcome of Board Meeting
-
Wanbury - Outcome of Board Meeting
-
Wanbury - Trading Window
-
Wanbury - Press Release
-
Wanbury - Announcement under Regulation 30 (LODR)-Press Release / Media Release
-
Wanbury - Disclosure under SEBI Takeover Regulations
-
Wanbury - Press Release
-
Wanbury - Announcement under Regulation 30 (LODR)-Press Release / Media Release
-
Wanbury - Press Release
-
Wanbury expands Global API Regulatory Filings
-
Wanbury - Announcement under Regulation 30 (LODR)-Press Release / Media Release
-
Wanbury - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Wanbury - Investor Presentation
-
Wanbury - Press Release
-
Wanbury - Announcement under Regulation 30 (LODR)-Press Release / Media Release
-
Wanbury Q4 net profit up 7.11% at Rs 21.70 cr
-
Wanbury - Outcome Of The Board Meeting Held On 29.05.2026
-
Wanbury - Board Meeting Outcome for Outcome Of The Board Meeting Held On 29.05.2026
-
Wanbury - Update on board meeting
-
Wanbury - Board Meeting Intimation for Notice Of Board Meeting For Approving The Audited Financial Results & Statements Of Th
-
Wanbury - Press Release
-
Wanbury - Announcement under Regulation 30 (LODR)-Press Release / Media Release
-
Wanbury - General Updates
-
Wanbury has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2026
-
Wanbury - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
-
Wanbury's Patalganga mfg facility receives CBPF (GMP) Certificate
Key fundamentals
Evaluate the intrinsic value of Wanbury Ltd stockÂ
| Name | March-26 | March-25 | March-24 | March-23 | March-22 |
|---|---|---|---|---|---|
| Assets | 359.9011 | 232.5001 | 137.8934 | 56.8788 | 69.2111 |
| Liabilities | 359.9011 | 232.5001 | 137.8934 | 56.8788 | 69.2111 |
| Equity | 34.9394 | 32.7705 | 32.7455 | 32.7055 | 32.6655 |
| Gross Profit | 106.7571 | 76.3192 | 70.0022 | 23.1719 | 35.3128 |
| Net Profit | 66.1347 | 30.5301 | 30.3995 | -10.3958 | 81.4739 |
| Cash From Operating Activities | 31.5301 | 26.1016 | 4.017 | 19.7972 | 40.5231 |
| NPM(%) | 10.17 | 5.09 | 5.28 | -2.08 | 15.93 |
| Revenue | 650.2683 | 599.5142 | 575.6498 | 499.6469 | 511.1857 |
| Expenses | 543.5112 | 523.195 | 505.6476 | 476.475 | 475.8729 |
| ROE(%) | 45.78 | 21.13 | 21.04 | -7.19 | 56.4 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|---|---|---|---|
| 29 Jul 2010 | 1 | 10 | 0 | 78.6 |
| 12 Mar 2009 | 0.5 | 5 | 0 | 45.5 |
| 13 Sep 2007 | 2 | 20 | 0 | 115 |
Peers
Other companies within the same industry or sector that are comparable to Wanbury Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Albert David Ltd | 705.05 | -0.47 | 0.00 | 159.03 | -26.19 | 0.71 |
| Lotus Eye Hospital and Institute Ltd | 123.23 | 0.87 | 4107.67 | 579.49 | 0.39 | 0.00 |
| Vaishali Pharma Ltd | 7.44 | 0.13 | 24.80 | 3635.33 | 15.42 | 0.00 |
| Astec Lifesciences Ltd | 687.15 | -1.75 | 0.00 | 546.47 | -363.14 | 0.00 |
Company Info
The Company was incorporated on 11th August 1988, as a Private Limited Company under the name of `Pearl Distributors Private Limited'. The name of the Company was changed to "Pearl Organics Private Limited" on 17th January, 1991. The Company was converted into a Public Limited Company on 6th August, 1991. The main object of the Company is to undertake the manufacture and sale of pharmaceuticals, medicines, drugs and organic chemicals. A substantial portion of the production of these products are intended for exports. The Company has set up a full-fledged export marketing division consisting of experienced professionals. The Company has already secured orders worth Rs 1.07 crores from West European Countries. The Company is in the process of negotiating further orders with foreign buyers for export of its products. The main objects of the Company are fully set out in Memorandum of Association of the Company. The Company has no subsidiary. The Company has been principally promoted by Mr.K. Chandran along with his associates Mr K Chandran has a rich experience of over 12 years in marketing of pharmaceutical formulation in local & international markets. During his 12 years tenure he has worked in various capacities including as business manager in one of the largest pharmaceutical company. He was also head of export division of an export oriented pharmaceutial Company. 2004 - Pearl Organics to establish new R&D centre in Mumbai 2006 - Wanbury acquires generic company in Spain 2007 - Wanbury Ltd has recommended dividend of Rs 2 per equity share i.e. @ 20% 2008 - Wanbury Ltd has recommended dividend of Rs 0.50 per equity shares i.e. @5% 2010 - Wanbury Ltd has recommended a dividend of Rs. 1/- per equity share 2016 - Wanbury Won Pharma IT Innovation Award 2016 - Wanbury bags 2 awards at recently held AWACS awards 2024 -Wanbury Limited received a Certificate of Suitability (CEP) forthe launch of its new product, Dextromethorphan (API). -Wanbury Limited wins two Safety Awards for its API Manufacturing site in Patalganga for the third consecutive year at the Maharashtra Safety Awards Competition 2023, conducted by Maharashtra State Government. 2025-Wanbury limited launches iron supplement "WANBURY CRED' to combat Anemia with Superior safety absorption.-Wanbury's active pharmaceutical ingredient (API) manufacturing facility in Patalganga has received the Certificate of Good Manufacturing Practices (CBPF) from ANVISA, the Brazilian Health Regulatory Agency.
The Company was incorporated on 11th August 1988, as a Private Limited Company under the name of `Pearl Distributors Private Limited'. The name of the Company was changed to "Pearl Organics Private Limited" on 17th January, 1991. The Company was converted into a Public Limited Company on 6th August, 1991. The main object of the Company is to undertake the manufacture and sale of pharmaceuticals, medicines, drugs and organic chemicals. A substantial portion of the production of these products are intended for exports. The Company has set up a full-fledged export marketing division consisting of experienced professionals. The Company has already secured orders worth Rs 1.07 crores from West European Countries. The Company is in the process of negotiating further orders with foreign buyers for export of its products. The main objects of the Company are fully set out in Memorandum of Association of the Company. The Company has no subsidiary. The Company has been principally promoted by Mr.K. Chandran along with his associates Mr K Chandran has a rich experience of over 12 years in marketing of pharmaceutical formulation in local & international markets. During his 12 years tenure he has worked in various capacities including as business manager in one of the largest pharmaceutical company. He was also head of export division of an export oriented pharmaceutial Company. 2004 - Pearl Organics to establish new R&D centre in Mumbai 2006 - Wanbury acquires generic company in Spain 2007 - Wanbury Ltd has recommended dividend of Rs 2 per equity share i.e. @ 20% 2008 - Wanbury Ltd has recommended dividend of Rs 0.50 per equity shares i.e. @5% 2010 - Wanbury Ltd has recommended a dividend of Rs. 1/- per equity share 2016 - Wanbury Won Pharma IT Innovation Award 2016 - Wanbury bags 2 awards at recently held AWACS awards 2024 -Wanbury Limited received a Certificate of Suitability (CEP) forthe launch of its new product, Dextromethorphan (API). -Wanbury Limited wins two Safety Awards for its API Manufacturing site in Patalganga for the third consecutive year at the Maharashtra Safety Awards Competition 2023, conducted by Maharashtra State Government. 2025-Wanbury limited launches iron supplement "WANBURY CRED' to combat Anemia with Superior safety absorption.-Wanbury's active pharmaceutical ingredient (API) manufacturing facility in Patalganga has received the Certificate of Good Manufacturing Practices (CBPF) from ANVISA, the Brazilian Health Regulatory Agency.
Read More
Parent Organisation
Wanbury Ltd.
Founded
11/08/1988
Managing Director
NSE Symbol
WANBURYEQ
FAQ
The current price of Wanbury Ltd is ₹ 278.85.
The 52-week high for Wanbury Ltd is ₹ 287.25 and the 52-week low is ₹ 277.90.
The market capitalization of Wanbury Ltd is currently ₹ 974.29. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Wanbury Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Wanbury Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Wanbury Ltd shares.
The CEO of Wanbury Ltd is , who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.
